Dendritic cell-activated chimeric antigen receptor and its use
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- SHENZHEN FRONTIERGATE BIOTECHNOLOGY CO LTD
- Filing Date
- 2021-12-24
- Publication Date
- 2026-05-21
AI Technical Summary
Tumor-infiltrating dendritic cells (TIDCs) exhibit immature or dysfunctional phenotypes in immunosuppressive tumor microenvironments, suppressing T-cell infiltration and activation, and existing methods to activate them have not been effectively translated into clinical applications.
A chimeric antigen receptor (CAR) is designed to include an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain to activate dendritic cells in immunosuppressive tumor microenvironments, comprising specific immunoinhibitory molecule targets and immunostimulatory cytokines, and is expressed in dendritic cells or their precursors using vectors like lentiviral vectors.
The CAR-activated dendritic cells enhance T-cell activation and immune response efficacy, particularly in tumors less responsive to CAR-T monotherapy, promoting immunostimulatory cytokine secretion and improved tumor cell recognition and elimination.
Smart Images

Figure 0007863565000003 
Figure 0007863565000004 
Figure 0007863565000005